Loading patent…
AssigneeAlto Neuroscience, Inc.
InventorsAmit ETKIN, Adam SAVITZ, Nicholas Cooper
Estimating the term…
This invention relates to the treatment of a psychiatric or neurological disorder in a patient in need thereof who has anhedonia (lack of pleasure or motivation to pursue rewarding activities) by administering irdabisant or a pharmaceutically acceptable salt thereof, either as a monotherapy, or in combination with an antipsychotic agent. Examples of such psychiatric or neurological disorder include major depressive disorder, bipolar depression (such as bipolar I or bipolar II disorders), post-traumatic stress disorder, substance use disorder, anhedonia-related aspects of schizophrenia (e.g., negative symptoms) and schizoaffective disorder (e.g., with mood and/or negative symptoms).
A method of treating a patient having a psychiatric or neurological disorder with anhedonia comprising administering to the patient an effective amount of irdabisant or a pharmaceutically acceptable salt thereof as the sole active agent.
A method of treating a patient having a psychiatric or neurological disorder with anhedonia comprising administering to the patient an effective amount of (a) irdabisant or a pharmaceutically acceptable salt thereof, and (b) an antipsychotic agent.
A method of treating anhedonia in a patient comprising administering to the patient an effective amount of irdabisant or a pharmaceutically acceptable salt thereof as the sole active agent or in combination with an antipsychotic agent.
A method of treating anhedonia in a patient having major depressive disorder comprising administering to the patient an effective amount of irdabisant or a pharmaceutically acceptable salt thereof as the sole active agent or in combination with an antipsychotic agent, antidepressant, or any combination of any of the foregoing.
A method for evaluating a drug for the treatment of depression (such as major depressive disorder) comprising, for each patient,
Dependencies are inferred from the claim text.